The company is an advanced materials enterprise that develops proprietary isotope enrichment technologies to serve nuclear medicine, semiconductor, and nuclear energy markets through its Aerodynamic Separation Process and Quantum Enrichment platforms. It produces enriched isotopes such as Carbon-14 for pharmaceutical development, Silicon-28 for quantum computing semiconductors, and Ytterbium-176 for cancer radiotherapy; develops High-Assay Low-Enriched Uranium for small modular reactors; operates helium and liquefied natural gas production from exceptional-concentration natural gas reserves; and maintains strategic equity investments in radiopharmaceutical and biotech companies. The company generates revenue through isotope tolling agreements and purchase orders, nuclear fuel supply contracts, direct sales of helium and LNG, and equity-backed strategic investments.